NucleoFill™

This product is not cleared by the FDA
for distribution in the United States.

rational

Degenerative disc disease affects many patients worldwide and is increasingly prevalent with the ageing of the world population. Aggressive procedures such as surgical fusion or TDR are not suitable for younger patients suffering from a limited, but incapacitating degenerative disease. A patient with limited disc prolapse and minor annulus tearing should undergo non-invasive surgery. The purpose of treating early disc degeneration with a nucleus replacement device is to restore disc height while decreasing back pain, and to enable patients to fully resume all their daily activities.

The NucleoFill™ project is co-financed by the European Union.

The Europe is involved in “Nord Pas-de-Calais” with the European fund of regional development.